Agilon Health Investors Face March 2 Deadline in Competing Securities Class Actions

Overview

• Wolf Haldenstein, Rosen Law Firm, Pomerantz, Kirby McInerney, and The Law Offices of Frank R. Cruz issued new notices this week seeking investors and lead‑plaintiff candidates.
• Investors who purchased AGL during the alleged periods must move by March 2, 2026 to be considered for lead‑plaintiff appointment.
• Filings define the class period differently, with some using February 6–August 4, 2025 and others February 26–August 4, 2025, which could affect eligibility.
• Complaints allege Agilon issued unachievable 2025 guidance and overstated the immediate benefits of its risk‑reduction “strategic actions.”
• The actions cite August 4, 2025 announcements—CEO Steven Sell’s departure, suspended full‑year guidance, and more acute industry headwinds—followed by a roughly 51% share‑price drop to $0.88, and no class has been certified.